SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors.

Ther Adv Med Oncol · 2024 · PMC11574894 · PMID 39563716

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Moreover, analyses of EORTC QLQ-C30 data showed a trend that 10 out of 15 HRQoL dimensions had longer TUDD in favor of sunitinib.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.